By Jefferey Jaxen

During a live-streamed meeting of the World Health Organization’s (WHO) briefing on monkeypox. General-Director Tedros Adhanom Ghebreyesus declared the virus outbreak a public health emergency of international concern.    

The targeted states and communities where cases are clustering are being directed to vaccinate by public health officials in hopes of stoping the spread. However, a major concern was voiced during that same WHO meeting by Unit Head of Global Infectious Hazards Preparedness at the WHO Tim Nguyen, when he stated: 

“I would like to underline one thing that is very important to WHO. We do have uncertainties around the effectiveness of these vaccines because they haven’t been used in this context and this scale before. And therefore, we are working with our member states, that when these vaccines are being delivered, that they are delivered in the context of clinical trial studies and prospectively collecting this data to increase our understanding on the effectiveness of these vaccines.” 

On June 28, HHS announced they would provide 296,000 doses of Bavarian Nordic’s JYNNEOS vaccine. Then, on July 1 they announced an order of an additional 2.5 million doses of the FDA-licensed vaccine indicated for prevention of smallpox and monkeypox yet stated that deliveries from this latest order will begin arriving at the Strategic National Stockpile (SNS) later this year and will continue through early 2023.

In concurrence with Nguyen’s warning to the WHO, the CDC similarly states: “We do not know if JYNNEOS will fully protect against monkeypox virus infection in this outbreak. Individuals wanting to minimize their risk of infection should take additional preventive measures and self-isolate as soon as they develop monkeypox symptoms, such as a rash.”

The 2019 approval of the JYNNEOS vaccine by the FDA, a third-generation monkeypox vaccine, was in-part a response to the poor safety profile of the 2007 FDA-approved, second-generation ACAM2000 vaccine which produced higher rates of heart inflammation and was contraindicated in severely immunocompromised people. Concerning the ACAM2000, the CDC websites states

“Adverse events following ACAM2000, including myopericarditis or Vaccinia virus transmission to household contacts, can be serious. ACAM2000 will be made available for individuals who decide in consultation with their healthcare provider that the potential benefits of vaccination outweighs any potential risks from ACAM2000 adverse events.”

However, during two of the pivotal clinical trials evaluating the JYNNEOS vaccine, a significant number (18.4%) of subjects were reported to have abnormal troponin levels, a indicator that damage to the heart has occurred, following vaccination

The WHO first reported there was no evidence the monkeypox virus had mutated three weeks after the first case was identified in the UK. That proclamation soon gave way to reports of two distinct variants circulating on June 3 according to the CDC

Being a DNA virus, monkeypox has a more stable genetic code and a vastly slower mutation rate than the RNA-based coronavirus meaning variants aren’t produced as rapidly.

Jefferey Jaxen

Jefferey Jaxen is a health journalist and featured in his weekly segment, ’The Jaxen Report’, on The HighWire. As an investigative journalist, researcher, and compelling writer, Jefferey serves as Lead editor of The HighWire News and Opinion Team.

Other Headlines

Coronavirus

Yale Study Finds Post-Vaccine Syndrome Shares Symptoms with Long COVID

A preprint study from Yale University researchers examined a condition known as post-vaccination syndrome. The study included 42 individuals with PVS and 22 without. Researchers observed elevated levels of spike proteins in the PVS group for 36 to 709 days because the time that lapsed since the last vaccination varied between participants. It is aContinue reading Yale Study Finds Post-Vaccine Syndrome Shares Symptoms with Long COVID

More news about Coronavirus

Health & Nutrition

Jury Slams Bayer With Nearly $2.1B Verdict Over Glyphosate Cancer Claims

A Georgia jury has ruled against Bayer in which a plaintiff claimed his use of Roundup caused his non-Hodgkin’s Lymphoma. The nearly $2.1 billion verdict is the largest payout the biotechnology company has paid out, as 60,000 lawsuits are still pending. The verdict includes $65 million in compensatory damages and $2 billion in punitive damages.Continue reading Jury Slams Bayer With Nearly $2.1B Verdict Over Glyphosate Cancer Claims

More news about Health & Nutrition

Vaccines

RFK Jr. Halts COVID-19 Oral Vaccine Trial for 90 Days, Ends Flu Vaccine Ad Campaign

HHS Secretary Robert F. Kennedy Jr. paused a clinical trial funded by the Biomedical Advanced Research and Development Authority (BARDA) for a COVID-19 oral vaccine made by Vaxart. Kennedy said, “While it is crucial that the Department [of] Health and Human Services (HHS) support pandemic preparedness, four years of the Biden administration’s failed oversight haveContinue reading RFK Jr. Halts COVID-19 Oral Vaccine Trial for 90 Days, Ends Flu Vaccine Ad Campaign

More news about Vaccines

Science & Tech

23andMe Files for Chapter 11 Bankruptcy; Genetic Data of 15 Million Users at Risk of Sale

The genetic data of 15 million people will soon be for sale as 23andMe has filed for Chapter 11 bankruptcy. The attorneys general for California and New York issued consumer alerts to advise consumers to take action to protect their data. New York AG Rob Bonta said “There’s health insurance companies that are interested inContinue reading 23andMe Files for Chapter 11 Bankruptcy; Genetic Data of 15 Million Users at Risk of Sale

More news about Science & Tech

Environment

Bayer Seeks Capital Raise to Cover Roundup Lawsuit Settlements

Bayer continues to face struggles related to its acquisition of Monsanto and the flagship product Roundup, which currently has 67,000 pending cases alleging the herbicide has caused serious health conditions. So far, Bayer has paid out $10 billion to settle cases and has $5.9 billion set aside to resolve the pending cases. Sources told ReutersContinue reading Bayer Seeks Capital Raise to Cover Roundup Lawsuit Settlements

More news about Environment

Policy

Peter Marks Resigns From FDA As HHS Fires 10,000 Employees In Reorganization Effort

Dr. Peter Marks, an FDA official involved in Operation Warp Speed, has resigned from his position as director of the Center for Biologics Evaluation and Research (CBER). Marks started his career at the FDA as deputy director of the CBER in 2012 and has been the director since 2016. CBER is tasked with ensuring biologicalContinue reading Peter Marks Resigns From FDA As HHS Fires 10,000 Employees In Reorganization Effort

More news about Policy